Amlodipine/Valsartan [Design Issues]

posted by Helmut Homepage – Vienna, Austria, 2023-09-12 08:48 (570 d 04:22 ago) – Posting: # 23717
Views: 3,438

Hi Bebac user,

❝ The combination of Amlodipine and valsartan was published as two periods crossover but after checking the variability of Valsartan, it had more than 30%. Therefore, should I in those cases design this study as replicated or un-replicated?


There is no product-specific guidance of the EMA and the FDA recommends 2×2×2 crossovers (fasting and fed). Any replicated design can be assessed for (conventional, unscaled) average bioequivalence. However, if you aim at reference-scaling, I would be wary to base the sample size on the CVw of a 2×2×2 design because the CVwR is unknown (see this article).

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,413 posts in 4,924 threads, 1,669 registered users;
57 visitors (0 registered, 57 guests [including 4 identified bots]).
Forum time: 13:10 CEST (Europe/Vienna)

Nothing shows a lack of mathematical education more
than an overly precise calculation.    Carl Friedrich Gauß

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5